Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiac involvement in hypertension.

D J DiPette1, E D Frohlich

  • 1Department of Medicine, University of Texas Medical Branch, Galveston 77550.

The American Journal of Cardiology
|June 15, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of the Ribonuclease Protection Assay for the Analysis and Characterization of Target mRNAs.

Methods in molecular medicine·2011
Same author

Bradykinin and prostaglandin E₁ regulate calcitonin gene-related peptide expression in cultured rat sensory neurons.

Regulatory peptides·2010
Same author

Calcitonin gene-related peptide and substance P contribute to reduced blood pressure in sympathectomized rats.

American journal of physiology. Heart and circulatory physiology·2005
Same author

Role of sensory nervous system vasoactive peptides in hypertension.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas·2002
Same author

Role of calcitonin gene-related peptide and substance P in Dahl-salt hypertension.

Hypertension (Dallas, Tex. : 1979)·2001
Same author

Omapatrilat in subtotal nephrectomy-salt hypertension: role of calcitonin gene-related peptide.

Hypertension (Dallas, Tex. : 1979)·2001
Same journal

Real-World Effectiveness and Tolerability of Sacubitril/Valsartan in Octogenarian Patients With Heart Failure: Results From the PARACHUTER Study.

The American journal of cardiology·2026
Same journal

ECG-Guided Conduction Pathways as a Lever to Shorten Post-TAVI Hospitalization.

The American journal of cardiology·2026
Same journal

Cystatin-C versus creatinine and kidney function in heart failure with preserved ejection fraction: a SOGALDI-PEF analysis.

The American journal of cardiology·2026
Same journal

Balloon-expandable versus Self-expanding Valves in Patients with Small Aortic Annuli Undergoing Transcatheter Aortic Valve Replacement.

The American journal of cardiology·2026
Same journal

Drug-Coated Balloons versus Drug-Eluting Stents following Coronary Atherectomy in Severely Calcified Lesions: A Systematic Review and Meta-Analysis.

The American journal of cardiology·2026
Same journal

Prehospital Statin Therapy and Outcomes in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

The American journal of cardiology·2026
See all related articles

Treating hypertension may not reduce coronary artery disease mortality, even with left ventricular (LV) hypertrophy regression. Some drugs improve LV mass and diastolic function, but their impact on cardiovascular events needs further study.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Pharmacology

Background:

  • Hypertension treatment and detection have improved, yet its impact on coronary artery disease mortality is unclear.
  • Left ventricular (LV) hypertrophy, a consequence of hypertension, is linked to increased mortality and ventricular arrhythmias.
  • Diastolic dysfunction, characterized by reduced ventricular distensibility, is an early sign in hypertensive hearts, preceding significant LV hypertrophy.

Purpose of the Study:

  • To investigate the unresolved effect of hypertension treatment on coronary artery disease-related mortality.
  • To explore the relationship between left ventricular hypertrophy regression and mortality reduction.
  • To determine if antihypertensive agents that improve LV hypertrophy and diastolic function also reduce cardiovascular event risk.

Related Experiment Videos

Main Methods:

  • Review of existing literature on hypertension, LV hypertrophy, and cardiovascular outcomes.
  • Analysis of echocardiographic findings in hypertensive patients regarding diastolic dysfunction.
  • Evaluation of the effects of various antihypertensive drug classes on LV mass and diastolic function.

Main Results:

  • The effect of hypertension treatment on coronary artery disease mortality remains uncertain.
  • LV hypertrophy is associated with increased mortality independent of other risk factors and linked to arrhythmias.
  • Diastolic dysfunction is an early finding in hypertension, detectable before significant LV hypertrophy.
  • Not all antihypertensive medications reduce LV mass or improve diastolic dysfunction.
  • Sympatholytic agents, calcium antagonists, beta-blockers, and ACE inhibitors show potential in reducing LV hypertrophy.

Conclusions:

  • Regression of LV hypertrophy may not directly translate to reduced mortality from coronary artery events.
  • Certain antihypertensive drug classes appear to reverse LV hypertrophy and improve diastolic dysfunction.
  • Further research is required to ascertain if these beneficial effects on LV structure and function translate to reduced coronary artery disease risk.